Q2041 HCPCS code: Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Q2041 is the HCPCS Level II code for axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case.

Code details

FieldValue
SectionQ codes — Temporary codes
Coverage codeC — Carrier judgment
Pricing indicator51 — Drug or biological (priced per ASP/average sales price rules)
BETOS categoryO1E — Other drugs
Added2018-04-01
Last action effective2019-01-01

What changed for Q2041

Frequently asked questions

What is HCPCS code Q2041?

Q2041 is the HCPCS Level II code for axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose. Short descriptor: "Axicabtagene ciloleucel car+".

Does Medicare cover Q2041?

Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.

Related Q20 codes

Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.

Next steps

Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.

All Q codes · HCPCS lookup